Shares of Shattuck Labs, Inc. (NASDAQ:STTK – Get Free Report) have received an average rating of “Moderate Buy” from the ten ratings firms that are currently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating and nine have issued a buy rating on the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $11.00.
A number of equities research analysts recently weighed in on STTK shares. Wall Street Zen raised shares of Shattuck Labs from a “hold” rating to a “buy” rating in a report on Saturday. Cantor Fitzgerald started coverage on shares of Shattuck Labs in a report on Monday, April 27th. They set an “overweight” rating for the company. Weiss Ratings lowered shares of Shattuck Labs from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, June 2nd. TD Cowen reaffirmed a “buy” rating on shares of Shattuck Labs in a report on Friday, March 6th. Finally, Wedbush raised their price target on shares of Shattuck Labs from $8.00 to $11.00 and gave the company an “outperform” rating in a report on Friday, May 8th.
View Our Latest Analysis on Shattuck Labs
Shattuck Labs Trading Down 6.5%
Shattuck Labs (NASDAQ:STTK – Get Free Report) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.01. During the same quarter last year, the business earned ($0.27) EPS. On average, analysts forecast that Shattuck Labs will post -0.51 earnings per share for the current fiscal year.
Insider Buying and Selling at Shattuck Labs
In other Shattuck Labs news, insider Arundathy N. Pandite sold 30,000 shares of the firm’s stock in a transaction on Tuesday, May 12th. The shares were sold at an average price of $6.61, for a total transaction of $198,300.00. Following the completion of the transaction, the insider directly owned 166,219 shares of the company’s stock, valued at $1,098,707.59. This trade represents a 15.29% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Clay B. Siegall acquired 62,500 shares of the firm’s stock in a transaction on Tuesday, June 9th. The shares were bought at an average cost of $4.00 per share, with a total value of $250,000.00. Following the completion of the acquisition, the director owned 318,608 shares in the company, valued at $1,274,432. This represents a 24.40% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. 8.79% of the stock is owned by company insiders.
Institutional Inflows and Outflows
Hedge funds have recently added to or reduced their stakes in the stock. Aberdeen Group plc grew its holdings in Shattuck Labs by 462.1% during the 4th quarter. Aberdeen Group plc now owns 531,177 shares of the company’s stock worth $1,939,000 after acquiring an additional 436,673 shares in the last quarter. NEXTBio Capital Management LP acquired a new position in Shattuck Labs during the 4th quarter worth $11,497,000. Pinnacle Associates Ltd. grew its holdings in Shattuck Labs by 1.8% during the 3rd quarter. Pinnacle Associates Ltd. now owns 1,388,723 shares of the company’s stock worth $3,319,000 after acquiring an additional 25,000 shares in the last quarter. EP Wealth Advisors LLC acquired a new position in Shattuck Labs during the 4th quarter worth $150,000. Finally, Invesco Ltd. acquired a new position in Shattuck Labs during the 4th quarter worth $103,000. 58.74% of the stock is owned by institutional investors and hedge funds.
About Shattuck Labs
Shattuck Labs, Inc (NASDAQ: STTK) is a clinical‐stage biotechnology company headquartered in Cambridge, Massachusetts. The company is focused on developing immunotherapeutic vaccines to prevent and treat substance use disorders, with an initial emphasis on opioids. Shattuck Labs employs a proprietary hapten‐carrier conjugate technology designed to generate high‐affinity drug‐specific antibodies that sequester target molecules in the bloodstream and reduce their passage across the blood‐brain barrier.
The company’s lead program targets fentanyl, a synthetic opioid responsible for a significant proportion of overdose fatalities.
Featured Articles
- Five stocks we like better than Shattuck Labs
- Gravity Check: Houston, SpaceX Has a Valuation Problem
- Strategy’s Bitcoin Rally Has a Hidden Engine
- Okta’s AI Moment May Be Bigger Than Investors Realize
- 3 Rate-Ready Stocks for the New Fed Chair’s First Big Test
Receive News & Ratings for Shattuck Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shattuck Labs and related companies with MarketBeat.com's FREE daily email newsletter.
